EGFR G719A

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma3
EGFR G719A	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4196 In a retrospective study of 46, Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR G719A mutation was associated with resistance to erlotinib treatment. The patient survived 9.… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC	civic
EGFR G719A AND MET Splice Site (c.2888-21_2888-20delinsGC)	Afatinib + CrizotinibCombination	Predictive	C	Supports Sensitivity Response	3	submitted	EID11466 A 60-year old man (smoker: 300 pack-years) presented with lung adenocarcinoma measuring 3.0 x 2.3 cm and multiple lymph node metastases. Next-generation sequencing revealed a EGFR G719A (abundance 5.0… (full text at CIViC) PMID 30922580 · Zeng et al., 2019 ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Adenocarcinoma3

EGFR G719A

Erlotinib

Predictive

Supports Sensitivity Response

—

submitted

EID4196

In a retrospective study of 46, Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR G719A mutation was associated with resistance to erlotinib treatment. The patient survived 9.… (full text at CIViC)

PMID 27032107 · De Grève et al., 2016 · Open in CIViC

civic

EGFR G719A AND MET Splice Site (c.2888-21_2888-20delinsGC)

Afatinib + CrizotinibCombination

Predictive

Supports Sensitivity Response

submitted

EID11466

A 60-year old man (smoker: 300 pack-years) presented with lung adenocarcinoma measuring 3.0 x 2.3 cm and multiple lymph node metastases. Next-generation sequencing revealed a EGFR G719A (abundance 5.0… (full text at CIViC)

PMID 30922580 · Zeng et al., 2019 ·

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
45225	Pathogenic	criteria provided, single submitter	1	Non-small cell lung carcinoma; Neoplasm	germline/somatic	3	Jan 04, 2013	clinvar

Variation

Clinical significance

Review status

Stars

Conditions

Origin

Submitters

Last evaluated

Source

45225

Pathogenic

criteria provided, single submitter

Non-small cell lung carcinoma; Neoplasm

germline/somatic

Jan 04, 2013

clinvar

Lung Non-Small Cell Carcinoma6
EGFR G719A	Erlotinib	Predictive	B	Supports Sensitivity Response	—	submitted	EID4195 In a study of 889 non-small cell lung cancer patients, mutations in the EGFR gene was observed in 11.1% of patients (58 of 518 sequenced). Patients with an EGFR mutation were associated with an improv… (full text at CIViC) PMID 20493771 · Cappuzzo et al., 2010 · Open in CIViC	civic
EGFR G719A	Erlotinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID4194 3 patients with stage IV non small cell lung adenocarcinoma with G719A mutation were given erlotinib. 1 patient was alive at end of study with progression free survival (PFS) of 27.2 months and overal… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC	civic
EGFR G719A	Erlotinib + GefitinibSubstitutes	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID6181 In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generati… (full text at CIViC) PMID 23749122 · Locatelli-Sanchez et al., 2013 · Open in CIViC	civic
EGFR G719A	Gefitinib	Predictive	C	Supports Sensitivity Response	—	accepted	EID2508 In a study of 297 non-small cell lung cancer patients, 15% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=22), L858R (n=16) and G719A (n=2). Patients with EGFR mutations … (full text at CIViC) PMID 20038723 · Douillard et al., 2010 · Open in CIViC	civic
EGFR G719A	Gefitinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID4193 3 patients with stage IV non small cell lung adenocarcinoma with G719A mutation were given gefitinib. The study reported progression free survival of 33.2, 5.8 and 0.2 months, and overall survival of … (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC	civic
EGFR G719A AND EGFR E709K	Erlotinib + GefitinibSubstitutes	Predictive	C	Supports Sensitivity Response	3	submitted	EID6036 Stage IIIB/IV patients with histologically proven NSCLC were enrolled in this study if the tumor cells bore EGFR mutations other than T790M. Patient with E709K and G719A demontrates PR and an early … (full text at CIViC) PMID 25179728 · Chang et al., 2015 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma6

EGFR G719A

Erlotinib

Predictive

Supports Sensitivity Response

—

submitted

EID4195

In a study of 889 non-small cell lung cancer patients, mutations in the EGFR gene was observed in 11.1% of patients (58 of 518 sequenced). Patients with an EGFR mutation were associated with an improv… (full text at CIViC)

PMID 20493771 · Cappuzzo et al., 2010 · Open in CIViC

civic

EGFR G719A

Erlotinib

Predictive

Supports Sensitivity Response

submitted

EID4194

3 patients with stage IV non small cell lung adenocarcinoma with G719A mutation were given erlotinib. 1 patient was alive at end of study with progression free survival (PFS) of 27.2 months and overal… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

civic

EGFR G719A

Erlotinib + GefitinibSubstitutes

Predictive

Does Not Support Sensitivity Response

accepted

EID6181

In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generati… (full text at CIViC)

PMID 23749122 · Locatelli-Sanchez et al., 2013 · Open in CIViC

civic

EGFR G719A

Gefitinib

Predictive

Supports Sensitivity Response

—

accepted

EID2508

In a study of 297 non-small cell lung cancer patients, 15% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=22), L858R (n=16) and G719A (n=2). Patients with EGFR mutations … (full text at CIViC)

PMID 20038723 · Douillard et al., 2010 · Open in CIViC

civic

EGFR G719A

Gefitinib

Predictive

Supports Sensitivity Response

submitted

EID4193

3 patients with stage IV non small cell lung adenocarcinoma with G719A mutation were given gefitinib. The study reported progression free survival of 33.2, 5.8 and 0.2 months, and overall survival of … (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

civic

EGFR G719A AND EGFR E709K

Erlotinib + GefitinibSubstitutes

Predictive

Supports Sensitivity Response

submitted

EID6036

Stage IIIB/IV patients with histologically proven NSCLC were enrolled in this study if the tumor cells bore EGFR mutations other than T790M. Patient with E709K and G719A demontrates PR and an early … (full text at CIViC)

PMID 25179728 · Chang et al., 2015 · Open in CIViC

civic

Evidence by cancer (9 items)

Clinical significance (1)